Generics Shares of Canada-based Bausch Health Companies were up 14.6% at $8.56 on Wednesday, after it said that a US district court stuck with an earlier judgment that prevented an application for a rival generic version of its Xifaxan (rifaximin) irritable bowel syndrome drug from getting US Food and Drug Administration (FDA) approval until 2029. 19 May 2023